ALCHEMIST A081105

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial). Click here to learn more.

ALCHEMIST A151216

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). Click here to learn more.

ALCHEMIST EA4512

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. Click here to learn more.

ARRAY 818-202 (JIT study)

Open-label, multicenter, non-randomized, Phase 2 study of the combination of encorafenib and binimetinib in patients with BRAFV600E-mutant metastatic NSCLC. Treatment will be administered in 28-day cycles and will continue until disease progression, unacceptable toxicity, withdrawal of consent, initiation of subsequent anticancer therapy, death, or the defined end of the study. Click here to learn more.

CA209-817

An Investigational Immuno-therapy Study for Safety and Efficacy of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers. Click here to learn more.

S1400F: Southwest Oncology Group

(LUNGMAP) Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer. Click here to learn more.

S1800A: Southwest Oncology Group

(LUNGMAP) Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial). Click here to learn more.

S1900A: Southwest Oncology Group

(LUNGMAP) Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial). Click here to learn more.

TAK300X3-A300X3 (BRIG3001)

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®). Click here to learn more.

 


Learn more about Lung Cancer >

Our Affiliations

 

 QCCA The Cancer FoundationNCI

We’re Here to Help! Click Below to Get Started